Can IMI Deliver Real Innovation for Europe? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Can IMI Deliver Real Innovation for Europe?
Has Europe's Innovative Medicines Initiative been successful in alleviating concerns regarding the region?s levels of pharmaceutical innovation?




Current status

Given that it can take nearly nine years for a drug candidate to advance from early clinical trials to the market, it is not surprising that the panel could only make preliminary conclusions about how productive IMI was, since it is still a very young initiative at this stage. However, IMI is characterised by a continuing high level of activity, which suggests that most stakeholder groups in the healthcare sector believe it can deliver on its promise of boosting European innovation. As of yet, there is no indication as to when an IMI project might result in a new drug, but it would certainly be a high profile method of demonstrating the initiative’s success. At the end of 2012, IMI launched its eighth call for projects. The call included a major focus on antimicrobial resistance, which is seen by the European Commission as an area where progress is urgently needed, given that the problem causes 25000 deaths annually and drains over €1.5 billion in healthcare expenses and productivity losses (6). It is in areas of unmet medical need such as this where IMI will be judged by those outside the pharmaceutical industry. If IMI only serves to enable pharmaceutical companies to remain commercially viable in the EU without also visibly serving social and public health objectives, there could be a backlash due to public funds having been used to such a major extent, and future public–private measures will be jeopardised.

References

1. EFPIA website, “The Pharmaceutical Industry in Figures,” www.efpia.eu, accessed 7 Feb., 2013.

2. European Commission website, “Healthcare Industries: High Level Group on Innovation and Provision of Medicines,” http://ec.europa.eu, accessed 7 Feb., 2013.

3. EurActiv website, “Scientists shun medicines project amid funding row,” www.euractiv.com, accessed 7 Feb., 2013.

4. LERU website, “LERU letter on the Innovative Medicines Initiative (IMI),” www.leru.org, accessed 7 Feb., 2013.

5. European Commission website, “First Interim Evaluation of the Innovative Medicines Initiative,” http://ec.europa.eu, accessed 7 Feb., 2013.

6. European Commission website, “Antimicrobial resistance,” http://ec.europa.eu, accessed 7 Feb., 2013.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here